Search results
- Boehringer Ingelheim will be initiating a Phase III clinical trial program to further investigate if BI 1015550 improves lung function in people with IPF and other forms of PPF, with the ambition to bring this medicine to patients as soon as possible.
www.boehringer-ingelheim.com › us › human-healthInvestigational treatment slowed lung function decline in IPF
IL-11 plays a key role in fibrosis across multiple organs and pre-clinical studies have shown that anti-IL-11 treatment has the potential to stop – and even reverse fibrosis – in different fibrotic diseases. Boehringer Ingelheim joined forces with Enleofen, a leader in IL-11 biology, in 2020.
People also ask
What is Boehringer Ingelheim fibroneer-IPF?
Is Boehringer Ingelheim a leader in pulmonary fibrosis treatment?
What is Boehringer Ingelheim BI 765423?
What is fibroneer TM -IPF?
Oct 26, 2022 · Ingelheim, Germany and Ridgefield, Conn, October 26, 2022 – Boehringer Ingelheim today announced that the first patient has enrolled in FIBRONEER™-IPF, a global Phase III trial evaluating BI 1015550, an investigational phosphodiesterase 4B (PDE4B) inhibitor, in people living with idiopathic pulmonary fibrosis (IPF).
May 9, 2023 · IL-11 plays a key role in fibrosis across multiple organs and pre-clinical studies have shown that anti-IL-11 treatment has the potential to stop – and even reverse fibrosis – in different ...
Oct 26, 2022 · The trial is part of the FIBRONEER ™ global program, which includes two Phase III studies—FIBRONEER ™-IPF in patients with IPF and FIBRONEER ™-ILD in people living with other progressive ...
Oct 28, 2022 · Boehringer Ingelheim has enrolled the first patient in FIBRONEER-IPF, a Phase 3 clinical trial evaluating the efficacy, safety, and tolerability of BI 1015550, an investigational therapy for people with idiopathic pulmonary fibrosis (IPF).
- Science Writer
May 19, 2023 · IL-11 plays a key role in fibrosis across multiple organs and pre-clinical studies have shown that anti-IL-11 treatment has the potential to stop – and even reverse fibrosis – in different fibrotic diseases. Boehringer Ingelheim joined forces with Enleofen, a leader in IL-11 biology, in 2020.
May 9, 2023 · IL-11 plays a key role in fibrosis across multiple organs and preclinical studies have shown that anti-IL-11 treatment has the potential to stop – and even reverse fibrosis – in different fibrotic diseases. Boehringer Ingelheim joined forces with Enleofen, a leader in IL-11 biology, in 2020.
